Human neutralizing antibodies elicited by SARS-CoV-2 infection

Cited by (1,008)

Items 401–500 of 1,008

1. Long-Term Persistence of Spike Protein Antibody and Predictive Modeling of Antibody Dynamics After Infection With Severe Acute Respiratory Syndrome Coronavirus 2
   L. Grandjean, Anja Saso, Arturo Torres Ortiz, T. Lam, J. Hatcher, Rosie Thistlethwayte, M. Harris, T. Best, Marina Johnson, H. Wagstaffe et al. · 2021 · Clinical Infectious Diseases
2. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants
   Denise Haslwanter, M. Eugenia Dieterle, Anna Z. Wec, Cecilia M. O’Brien, Mrunal Sakharkar, Catalina Florez, Karen Tong, C. Garrett Rappazzo, Gorka Lasso, Olivia Vergnolle et al. · 2021 · mBio
3. Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection
   Julien Favresse, Christine Eucher, Marc Elsen, Constant Gillot, Sandrine Van Eeckhoudt, Jean‐Michel Dogné, Jonathan Douxfils · 2021 · Microorganisms
4. Notable sequence homology of the ORF10 protein introspects the architecture of SARS-CoV-2
   Sk. Sarif Hassan, Diksha Attrish, Shinjini Ghosh, Pabitra Pal Choudhury, Vladimir Nikolaevich Uversky, Alaa A. A. Aljabali, Kenneth H. Lundstrom, Bruce D. Uhal, Nima Rezaei, Murat Seyran et al. · 2021 · International Journal of Biological Macromolecules
5. Cross-reactive antibodies against human coronaviruses and the animal coronavirome suggest diagnostics for future zoonotic spillovers
   S. Klompus, S. Leviatan, T. Vogl, R. Mazor, I. Kalka, Liat Stoler-Barak, Nachum Nathan, Ayelet Peres, L. Moss, A. Godneva et al. · 2021 · Science immunology
6. Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy
   Xin Wu Zeng, Lingfang Li, Jing Lin, Xinlei Li, Bin Liu, Yang Kong, Shunze Zeng, Jianhua Du, Huahong Xiao, Tao Zhang et al. · 2020 · Antibody Therapeutics
7. SARS-CoV-2/COVID-19: Evolving Reality, Global Response, Knowledge Gaps, and Opportunities
   Marcin Filip Osuchowski, Federico Mario Aletti, Jean‐Marc Cavaillon, Stefanie B. Flohé, Evangelos J. Giamarellos‐Bourboulis, Markus Stefan Huber-Lang, Borna Relja, Tomasz Skirecki, Andrea Szabó, Marc Maegele · 2020 · Shock
8. Novel therapeutic approaches for treatment of COVID-19
   Nikoo Hossein‐Khannazer, Bahare Shokoohian, Anastasia I. Shpichka, Hamid Asadzadeh Aghdaei, Peter S. Timashev, Massoud Vosough · 2020 · Journal of Molecular Medicine
9. Hyperinflammation and Immune Response Generation in COVID-19
   K.P. Mishra, Ajay Kumar Singh, Shashi Bala Singh · 2020 · NeuroImmunoModulation
10. Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors
    M. Mor, M. Werbner, J. Alter, Modi Safra, Elad Chomsky, J. C. Lee, Smadar Hada-Neeman, Ksenia Polonsky, C. Nowell, A. Clark et al. · 2021 · PLoS Pathogens
11. Efficient discovery of SARS-CoV-2-neutralizing antibodies via B-cell receptor sequencing and ligand blocking
    Andrea R. Shiakolas, Kevin J. Kramer, N. Johnson, Steven C. Wall, Naveenchandra Suryadevara, D. Wrapp, S. Periasamy, Kelsey A. Pilewski, Nagarajan Raju, Rachel S. Nargi et al. · 2022 · Nature Biotechnology
12. Advances in Nanomaterial-Based Platforms to Combat COVID-19: Diagnostics, Preventions, Therapeutics, and Vaccine Developments
    Niaz Mahmud, Muzahidul Islam Anik, M. Khalid Hossain, Md Ishak Khan, Shihab Uddin, Md. Ashrafuzzaman, Md Mushfiqur Rahaman · 2022 · ACS Applied Bio Materials
13. Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications
    Endeshaw Chekol Abebe, Tadesse Asmamaw Dejenie · 2023 · Frontiers in Immunology
14. NeutrobodyPlex—monitoring SARS-CoV-2 neutralizing immune responses using nanobodies
    Teresa R. Wagner, Philipp D. Kaiser, Marius Gramlich, Elena Ostertag, Natalia Ruétalo, Daniel Junker, Julia Häring, Bjoern Traenkle, Matthias Becker, Alex Dulovic et al. · 2021 · EMBO Reports
15. Dynamics of B cell repertoires and emergence of cross-reactive responses in patients with different severities of COVID-19
    Zachary Montague, Huibin Lv, J. Otwinowski, William S. DeWitt, G. Isacchini, Garrick K. Yip, Wilson W. Ng, O. Tsang, M. Yuan, Hejun Liu et al. · 2021 · Cell Reports
16. High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells
    Jennifer Chen, Ryan Dz-Wei Chow, Eric Song, Tianyang Mao, Benjamin Israelow, Kathy Kamath, Joel D. Bozekowski, Winston A. Haynes, Renata B. Filler, Bridget L. Menasché et al. · 2022 · Science Immunology
17. Structural Basis of SARS-CoV-2– and SARS-CoV–Receptor Binding and Small-Molecule Blockers as Potential Therapeutics
    Hariharan Sivaraman, Shi Yin Er, Yeu Khai Choong, Edem Gavor, Jayaraman Sivaraman · 2020 · The Annual Review of Pharmacology and Toxicology
18. Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020)
    David S. Kim, S. Rowland-Jones, E. Gea-Mallorquí · 2020 · Frontiers in Immunology
19. Identification of cross-reactive CD8+ T cell receptors with high functional avidity to a SARS-CoV-2 immunodominant epitope and its natural mutant variants
    Chao Hu, M. Shen, Xiao-Jian Han, Qian Chen, Luo Li, Si-Yin Chen, Jing Zhang, Feng-xia Gao, Wen Wang, Ying-Ming Wang et al. · 2020 · bioRxiv
20. Protective neutralizing epitopes in SARS‐CoV‐2
    Hejun Liu, Ian A. Wilson · 2022 · Immunological Reviews
21. Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants
    Bin Ju, Qi Zhang, Ziyi Wang, Zhen Qin Aw, Peng Chen, Bing Zhou, Ruoke Wang, Xiangyang Ge, Qining Lv, Lin Cheng et al. · 2023 · Nature Immunology
22. Monoclonal antibodies: From magic bullet to precision weapon
    Hassan Aboul-Ella, Asmaa Gohar, Aya Ahmed Ali, Lina M. Ismail, Adham Ezz El-Regal Mahmoud, Walid Faisal Elkhatib, Heba Aboul-Ella · 2024 · Molecular Biomedicine
23. Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster
    M. Brustolin, J. Rodón, M. L. Rodríguez de la Concepción, C. Ávila-Nieto, G. Cantero, M. Pérez, Nigeer Te, M. Noguera-Julián, V. Guallar, Alfonso Valencia et al. · 2021 · Emerging Microbes and Infections
24. On the road to ending the COVID-19 pandemic: Are we there yet?
    J. Case, Emma S. Winkler, J. Errico, Michael S. Diamond · 2021 · Virology
25. Development of a Vaccine against SARS-CoV-2 Based on the Receptor-Binding Domain Displayed on Virus-Like Particles
    Lisha Zha, Xinyue Chang, Hongxin Zhao, Mona Omar Mohsen, Liang Hong, Yuhang Zhou, Hongquan Chen, Xuelan Liu, Jie Zhang, Dong Li et al. · 2021 · Vaccines
26. Boosting of cross-reactive antibodies to endemic coronaviruses by SARS-CoV-2 infection but not vaccination with stabilized spike
    Andrew R. Crowley, Harini Natarajan, Andrew P. Hederman, Carly A. Bobak, Joshua A. Weiner, Wendy Wieland-Alter, Jiwon Lee, Evan M. Bloch, Aaron A.R. Tobian, Andrew D. Redd et al. · 2022 · eLife
27. Antibody-like proteins that capture and neutralize SARS-CoV-2
    Taishi Kondo, Yasumasa Iwatani, Kazuhiro Matsuoka, Tomoshige Fujino, Shun Umemoto, Yoshiyuki Yokomaku, K. Ishizaki, Seita Kito, T. Sezaki, Gosuke Hayashi et al. · 2020 · Science Advances
28. An Overview of the Crystallized Structures of the SARS-CoV-2
    Mihaela Ileana Ionescu · 2020 · The Protein Journal
29. Prevalence of IgG antibodies to SARS-CoV-2 in Wuhan -implications for the ability to produce long-lasting protective antibodies against SARS-CoV-2
    Tao Liu, Sanyun Wu, Huangheng Tao, Guang Zeng, Fuling Zhou, F. Guo, Xing-Huan Wang · 2020 · medRxiv
30. The contribution of veterinary public health to the management of the COVID-19 pandemic from a One Health perspective
    Maurizio Ferri, Meredith Lloyd-Evans · 2021 · One Health
31. Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment
    Norma A. Valdez-Cruz, E. García-Hernández, C. Espitia, L. Cobos-Marín, C. Altamirano, Carlos G. Bando-Campos, L. F. Cofas-Vargas, E. W. Coronado-Aceves, Ricardo A. González-Hernández, Pablo Hernández-Peralta et al. · 2021 · Microbial Cell Factories
32. Rapid lateral flow tests for the detection of SARS-CoV-2 neutralizing antibodies
    Jianfu J. Wang, Nan Zhang, Sarah A. Richardson, Jin V. Wu · 2021 · Expert Review of Molecular Diagnostics
33. IgG antibodies against SARS-CoV-2 decay but persist 4 months after vaccination in a cohort of healthcare workers
    Giulia Brisotto, Elena Muraro, Marcella Montico, Chiara Corso, Chiara Evangelista, Mariateresa Casarotto, Cristina Caffau, Roberto Vettori, Maria Rita Cozzi, Stefania Zanussi et al. · 2021 · Clinica Chimica Acta
34. Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance
    Lirong Cao, Jingzhi Lou, See Yeung Chan, Hong Zheng, Caiqi Liu, Shi Zhao, Qi Li, Chris Ka Pun Mok, Renee W. Y. Chan, Ka Chun Chong et al. · 2022 · Nature Medicine
35. Monoclonal Antibody Therapeutics for Infectious Diseases: Beyond Normal Human Immunoglobulin
    Ryota Otsubo, Teruhito Yasui · 2022 · Pharmacology & Therapeutics
36. Variations within the Glycan Shield of SARS-CoV-2 Impact Viral Spike Dynamics
    M. Newby, C. Fogarty, J. Allen, J. Butler, E. Fadda, M. Crispin · 2022 · Journal of Molecular Biology
37. Targeting the SARS-CoV-2-spike protein: from antibodies to miniproteins and peptides
    Sebastian J. Pomplun · 2020 · RSC Medicinal Chemistry
38. Epitope profiling reveals binding signatures of SARS-CoV-2 immune response in natural infection and cross-reactivity with endemic human CoVs
    Caitlin I. Stoddard, Jared Galloway, Helen Y. Chu, Mackenzie M. Shipley, Kevin Sung, Hannah L. Itell, Caitlin R. Wolf, Jennifer K. Logue, Ariana Magedson, Meghan E. Garrett et al. · 2021 · Cell Reports
39. Dynamic Profiling of Binding and Allosteric Propensities of the SARS-CoV-2 Spike Protein with Different Classes of Antibodies: Mutational and Perturbation-Based Scanning Reveals the Allosteric Duality of Functionally Adaptable Hotspots
    Gennady M. Verkhivker, Steve Agajanian, Deniz Yaşar Öztaş, Grace Gupta · 2021 · Journal of Chemical Theory and Computation
40. Characterization of a Pan-Immunoglobulin Assay Quantifying Antibodies Directed against the Receptor Binding Domain of the SARS-CoV-2 S1-Subunit of the Spike Protein: A Population-Based Study
    Anna Schaffner, Lorenz Risch, Stefanie Aeschbacher, Corina Risch, Myriam C. Weber, Sarah L. Thiel, Katharina Jüngert, Michael Pichler, Kirsten Grossmann, Nadia Wohlwend et al. · 2020 · Journal of Clinical Medicine
41. Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021
    Kun Xu, Lianpan Dai, George F. Gao · 2021 · International Immunology
42. Cross-species transmission, evolution and zoonotic potential of coronaviruses
    Qian Li, Taif Shah, Binghui Wang, Linyu Qu, Rui Wang, Yutong Hou, Zulqarnain Baloch, Xueshan Xia · 2023 · Frontiers in Cellular and Infection Microbiology
43. Antibody Response to SARS-CoV-2 Membrane Protein in Patients of the Acute and Convalescent Phase of COVID-19
    Philipp Jörrißen, Paula Schütz, Matthias Weiand, Richard Vollenberg, Inga Marie Schrempf, Kevin Ochs, Christopher Frömmel, Phil‐Robin Tepasse, Hartmut Schmidt, Andree Zibert · 2021 · Frontiers in Immunology
44. SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients
    Tatjana Schwarz, Kirsten Heiß, Yuvaraj Mahendran, Fiordiligie Casilag, Florian Kurth, Leif Erik Sander, Clemens‐Martin Wendtner, Manuela A. Hoechstetter, Marcel A. Müller, Renate Sekul et al. · 2021 · Frontiers in Immunology
45. Global characterization of B cell receptor repertoire in COVID-19 patients by single-cell V(D)J sequencing
    Xiyun Jin, Wenyang Zhou, Meng Luo, Pingping Wang, Zhaochun Xu, Kexin Ma, Huimin Cao, Chang Xu, Yan Huang, Rui Cheng et al. · 2021 · Briefings in Bioinformatics
46. Evolutionary Tracking of SARS-CoV-2 Genetic Variants Highlights an Intricate Balance of Stabilizing and Destabilizing Mutations
    Jobin John Jacob, Karthick Vasudevan, Agila Kumari Pragasam, Karthik Gunasekaran, Balaji Veeraraghavan, Ankur Mutreja · 2021 · mBio
47. Establishment of replication-competent vesicular stomatitis virus-based recombinant viruses suitable for SARS-CoV-2 entry and neutralization assays
    Hongyue Li, Chaoyue Zhao, Yuhang Zhang, Fei Yuan, Qi Zhang, Xuanling Shi, Linqi Zhang, Cheng‐Feng Qin, Aihua Zheng · 2020 · Emerging Microbes & Infections
48. Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients
    Lafon, Eliott, Diem, Gabriel, Witting, Christina, Zaderer, Viktoria, Bellmann-Weiler, Rosa Maria, Reindl, Markus, Bauer, Angelika, Griesmacher, Andrea, Fux, Vilmos, Hoermann, Gregor et al. · 2021 · Frontiers in Immunology
49. Neurological injuries in COVID-19 patients: direct viral invasion or a bystander injury after infection of epithelial/endothelial cells
    Sayed Ausim Azizi, Saara‐Anne Azizi · 2020 · Journal of NeuroVirology
50. Neutralizing monoclonal antibodies for COVID-19 treatment and prevention
    J. Jaworski · 2020 · Biomedical Journal
51. Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants
    Tingting Li, Xiaojian Han, Chenjian Gu, Hangtian Guo, Huajun Zhang, Yingming Wang, Chao Hu, Kai Wang, Fengjiang Liu, Feiyang Luo et al. · 2021 · Nature Communications
52. SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
    Sho Iketani, David D. Ho · 2024 · Cell chemical biology
53. Lactiplantibacillus plantarum as a Potential Adjuvant and Delivery System for the Development of SARS-CoV-2 Oral Vaccines
    Julio Villena, Chang Li, María Guadalupe Vizoso-Pinto, Jacinto Sacur, Linzhu Ren, Haruki Kitazawa · 2021 · Microorganisms
54. Analysis of B Cell Receptor Repertoires Reveals Key Signatures of the Systemic B Cell Response after SARS-CoV-2 Infection
    Yu-Di Zhang, Q. Yan, K. Luo, P. He, Rui-Tian Hou, Xinwei Zhao, Qian Wang, Haisu Yi, Huan Liang, Yijun Deng et al. · 2021 · Journal of Virology
55. Early computational detection of potential high-risk SARS-CoV-2 variants
    2023
56. SARS-CoV-2 antibody testing for estimating COVID-19 prevalence in the population
    Thomas J. Vogl, Sigal Leviatan, Eran Segal · 2021 · Cell Reports Medicine
57. Evidence of a putative glycosaminoglycan binding site on the glycosylated SARS-CoV-2 spike protein N-terminal domain
    Zachariah P. Schuurs, Edward Hammond, Stefano Elli, Timothy Robert Rudd, Courtney J. Mycroft‐West, Marcelo Andrade de Lima, Mark Andrew Skidmore, Richard Torbjörn Gustav Karlsson, Yen‐Hsi Chen, Ieva Bagdonaite et al. · 2021 · Computational and Structural Biotechnology Journal
58. SARS-CoV-2 reinfection in patients negative for immunoglobulin G following recovery from COVID-19
    Ayad M. Ali, Kashif Ali, Mohammed Hassan Fatah, Hassan Mohammad Tawfeeq, Hassan Muhammad Rostam · 2021 · New Microbes and New Infections
59. Neutralizing antibody responses following natural SARS-CoV-2 infection: Dynamics and correlation with commercial serologic tests.
    Isabel Montesinos, Hafid Dahma, Fleur Wolff, Nicolás Dauby, Sabrina Delaunoy, Magaly Wuyts, Cedric Detemmerman, Cécile Duterme, Olivier Vandenberg, Charlotte Martin et al. · 2021 · Journal of Clinical Virology
60. A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2
    Thomas S. Fulford, Huy Trần Văn, Nicholas A. Gherardin, Shuning Zheng, Marcin Ciula, Heidi E. Drummer, Samuel J. Redmond, Hyon‐Xhi Tan, Irene Boo, Fan Li et al. · 2021 · EBioMedicine
61. Engineering ACE2 decoy receptors to combat viral escapability
    Takao Arimori, Nariko Ikemura, Toru Okamoto, Junichi Takagi, Daron M. Standley, Atsushi Hoshino · 2022 · Trends in Pharmacological Sciences
62. COVID-19 : physiopathologie d’une maladie à plusieurs visages
    Vincent Bonny, Alexis Maillard, Cyril Mousseaux, Léo Plaçais, Quentin Richier · 2020 · La Revue de Médecine Interne
63. A high-affinity RBD-targeting nanobody improves fusion partner’s potency against SARS-CoV-2
    Hebang Yao, Hongmin Cai, Tingting Li, Bingjie Zhou, Wenming Qin, Dimitri Lavillette, Dianfan Li · 2021 · PLoS Pathogens
64. Original Antigenic Sin: the Downside of Immunological Memory and Implications for COVID-19
    Eric L. Brown, Heather T. Essigmann · 2021 · mSphere
65. Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance
    C. Chakraborty, M. Bhattacharya, A. R. Sharma · 2021 · Current opinion in pharmacology (Print)
66. Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination
    William N. Voss, Michael L. Mallory, Patrick O. Byrne, Jeffrey Marchioni, Sean A. Knudson, John M. Powers, Sarah R. Leist, Bernadeta Dadonaite, Douglas R. Townsend, Jessica Kain et al. · 2024 · Cell Reports Medicine
67. Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation
    Lauren M. Meyers, Andrés H. Gutiérrez, Christine Boyle, Frances E. Terry, Bethany McGonnigal, Andres Μ. Salazar, Michael F. Princiotta, Wiliam D. Martin, Anne Searls De Groot, Leonard Moise · 2021 · npj Vaccines
68. Longitudinal Systemic and Mucosal Immune Responses to SARS-CoV-2 Infection
    Peter F. Wright, Alejandra Prevost-Reilly, Harini Natarajan, Elizabeth Bailey Brickley, Ruth I. Connor, Wendy Wieland‐Alter, Anna S Miele, Joshua A. Weiner, Robert D Nerenz, Margaret E. Ackerman · 2022 · The Journal of Infectious Diseases
69. Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2
    Mohd Zulkifli Salleh, Mohd Nor Norazmi, Zakuan Zainy Deris · 2022 · PeerJ
70. Evaluating the serological status of COVID-19 patients using an indirect immunofluorescent assay, France
    Sophie Edouard, Philippe Colson, Cléa Melenotte, Fabrizio Di Pinto, L. Thomas, Bernard La Scola, Matthieu Million, Hervé Tissot‐Dupont, Philippe Gautret, Andréas Stein et al. · 2020 · European Journal of Clinical Microbiology & Infectious Diseases
71. Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer
    Tatjana Bilich, Malte Roerden, Yacine Maringer, Annika Nelde, Jonas S. Heitmann, Marissa Lisa Dubbelaar, Andreas Peter, Sebastian Hörber, Jens Bauer, Jonas Rieth et al. · 2021 · Cancer Discovery
72. Antibody feedback contributes to facilitating the development of Omicron-reactive memory B cells in SARS-CoV-2 mRNA vaccinees
    Takeshi Inoue, Ryo Shinnakasu, C. Kawai, Hiromi Yamamoto, S. Sakakibara, Chikako Ono, Yumi Itoh, T. Terooatea, Kazuo Yamashita, Toru Okamoto et al. · 2022 · Journal of Experimental Medicine
73. Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection
    J. Guenthoer, M. Lilly, Tyler N. Starr, Bernadeta Dadonaite, Klaus N. Lovendahl, Jacob T. Croft, Caitlin I. Stoddard, V. Chohan, Shi-Lei Ding, Felicitas Ruiz et al. · 2023 · Proceedings of the National Academy of Sciences of the United States of America
74. Pathophysiology and clinical management of coronavirus disease (COVID-19): a mini-review
    Ying Zhu, Lokesh Sharma, De Chang · 2023 · Frontiers in Immunology
75. Perspectives on the development of neutralizing antibodies against SARS-CoV-2
    Mitchell Ho · 2020 · Antibody Therapeutics
76. 50 Years of structural immunology
    Ian A. Wilson, Robyn L. Stanfield · 2021 · Journal of Biological Chemistry
77. Thiol-based chemical probes exhibit antiviral activity against SARS-CoV-2 via allosteric disulfide disruption in the spike glycoprotein
    Yunlong Shi, Ari Zeida, Caitlin E. Edwards, Michael L. Mallory, Santiago Sastre, Matías Rodrigo Machado, Raymond John Pickles, Ling Lin Fu, Keke Liu, Jing Hui Yang et al. · 2022 · Proceedings of the National Academy of Sciences
78. Cryo-EM Structures Delineate a pH-Dependent Switch that Mediates Endosomal Positioning of SARS-CoV-2 Spike Receptor-Binding Domains
    Tongqing Zhou, Yaroslav Tsybovsky, Adam S. Olia, Jason Gorman, Micah Rapp, Gabriele Cerutti, Gwo‐Yu Chuang, Phinikoula S. Katsamba, Alexandra F. Nazzari, Jared M. Sampson et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
79. COVID-19 infection and liver injury: Clinical features, biomarkers, potential mechanisms, treatment, and management challenges
    Gholam Reza Sivandzadeh, Hassan Askari, Ali Reza Safarpour, Fardad Ejtehadi, Ehsan Raeis-Abdollahi, Armaghan Vaez LARI, Mohammad Foad Abazari, Firoozeh Tarkesh, Kamran Bagheri Lankarani · 2021 · World Journal of Clinical Cases
80. Fluorescence‐Quenching Lateral Flow Immunoassay for “Turn‐On” and Sensitive Detection of Anti‐SARS‐Cov‐2 Neutralizing Antibodies in Human Serum
    Lun Bian, Fu Qiangqiang, Zhuoheng Gan, Ze Wu, Yuchen Song, Yufeng Xiong, Fang Hu, Lei Zheng · 2023 · Advanced Science
81. Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries
    Yongbing Pan, Jian-Hui Du, Jia Liu, Hai Wu, Fang Gui, Nan Zhang, Xiao-Jie Deng, Gang Song, Yufeng Li, Jia Lu et al. · 2021 · Cell Discovery
82. Kinetics and isotype assessment of antibodies targeting the spike protein receptor‐binding domain of severe acute respiratory syndrome‐coronavirus‐2 in COVID‐19 patients as a function of age, biological sex and disease severity
    Nancy R. Graham, Annalis Whitaker, Camilla A. Strother, Ashley K. Miles, Dore Grier, Benjamin D. McElvany, Emily A. Bruce, Matthew E. Poynter, Kristen K. Pierce, Beth D. Kirkpatrick et al. · 2020 · Clinical & Translational Immunology
83. Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic
    Ya-Ping Sun, Mitchell Ho · 2020 · Antibody Therapeutics
84. Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective
    Yang Huang, Hui Sun, Hai Yu, Shaowei Li, Q. Zheng, N. Xia · 2020 · Antibody Therapeutics
85. Development of a Fast SARS-CoV-2 IgG ELISA, Based on Receptor-Binding Domain, and Its Comparative Evaluation Using Temporally Segregated Samples From RT-PCR Positive Individuals
    Farha Mehdi, Souvick Chattopadhyay, Ramachandran Thiruvengadam, Yadav Sarla, Manjit Kumar, Sangita Kumari Sinha, Sandeep Goswami, Pallavi Kshetrapal, Nitya Wadhwa, Uma Chandra Mouli Natchu et al. · 2021 · Frontiers in Microbiology
86. Durable antibody response one year after hospitalization for COVID-19: A longitudinal cohort study
    Mar Masiá, Marta Fernández‐González, Guillermo Telenti, Vanesa Agulló, José Alberto García, Sergio Padilla, Javier García‐Abellán, Antonio Galiana, Nieves Gonzalo-Jiménez, Félix Gutiérrez · 2021 · Journal of Autoimmunity
87. Omicron – The new SARS‐CoV‐2 challenge?
    Alexandra Lino, Marita A. Cardoso, Paula Martins‐Lopes, Helena M. R. Gonçalves · 2022 · Reviews in Medical Virology
88. Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients
    Q. Yan, P. He, Xiaohan Huang, K. Luo, Yu-Di Zhang, Haisu Yi, Qian Wang, Feng Li, Rui-Tian Hou, Xiaodi Fan et al. · 2021 · Emerging Microbes and Infections
89. Prospects of Neutralizing Nanobodies Against SARS-CoV-2
    Fangfang Chen, Zhihong Liu, Fan Jiang · 2021 · Frontiers in Immunology
90. Monoclonal antibody targeting the conserved region of the SARS-CoV-2 spike protein to overcome viral variants
    Wan-Ling Wu, Chen-Yi Chiang, Szu-Chia Lai, Chia-Yi Yu, Yu‐Ling Huang, Hung‐Chun Liao, Ching‐Len Liao, Hsin–Wei Chen, Shih‐Jen Liu · 2022 · JCI Insight
91. Developing a multiepitope vaccine for the prevention of SARS-CoV-2 and monkeypox virus co-infection: A reverse vaccinology analysis
    Fan Jiang, Yinping Liu, Yong Xue, Peng Cheng, Jie Wang, Jianqi Lian, Wenping Gong · 2023 · International Immunopharmacology
92. A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses
    Alexandra Tauzin, Manon Nayrac, Mehdi Benlarbi, Shang Yu Gong, Romain Gasser, Guillaume Beaudoin-Bussières, Nathalie Brassard, Annemarie Laumaea, Dani Vézina, Jérémie Prévost et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
93. Antibody Affinity Governs the Inhibition of SARS-CoV-2 Spike/ACE2 Binding in Patient Serum
    S. Fiedler, Monika A. Piziorska, Viola Denninger, A. Morgunov, A. Ilsley, Anisa Y. Malik, Matthias M. Schneider, S. Devenish, G. Meisl, V. Kosmoliaptsis et al. · 2021 · ACS Infectious Diseases
94. Antigenic sin of wild-type SARS-CoV-2 vaccine shapes poor cross-neutralization of BA.4/5/2.75 subvariants in BA.2 breakthrough infections
    Bin Ju, Qing Fan, Miao Wang, Xuejiao Liao, Huimin Guo, Haiyan Wang, Xiangyang Ge, Lei Liu, Zheng Zhang · 2022 · Nature Communications
95. Thermodynamics of the Interaction between the Spike Protein of Severe Acute Respiratory Syndrome Coronavirus‑2 and the Receptor of Human Angiotensin-Converting Enzyme 2. Effects of Possible Ligands
    Cristina García‐Iriepa, Cécilia Hognon, Antonio Francés‐Monerris, Isabel Iriepa, Tom Miclot, Giampaolo Barone, Antonio Monari, Marco Marazzi · 2020 · The Journal of Physical Chemistry Letters
96. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
    Ligong Lu, Hui Zhang, Meixiao Zhan, Jun Jiang, Hua Yin, Danielle J. Dauphars, Shi-You Li, Yong Li, You-Wen He · 2020 · Science China Life Sciences
97. Seropositivity in blood donors and pregnant women during the first year of SARS‐CoV‐2 transmission in Stockholm, Sweden
    Xaquín Castro Dopico, Sandra Muschiol, Murray Christian, Leo Hanke, Daniel J. Sheward, Nastasiya F. Grinberg, Joanna Rorbach, Gordana Bogdanović, Gerald M. McInerney, Tobias Allander et al. · 2021 · Journal of Internal Medicine
98. Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay
    Ester López, Ebene R. Haycroft, Amy Adair, Francesca L. Mordant, Matthew T. O’Neill, Phillip Pymm, Samuel J. Redmond, Wen Shi Lee, Nicholas A. Gherardin, Adam K. Wheatley et al. · 2021 · JCI Insight
99. RBD-Modified Bacterial Vesicles Elicited Potential Protective Immunity against SARS-CoV-2
    Zhongqian Yang, Liangqun Hua, Mengli Yang, Shu-Qun Liu, Jianxin Shen, Weiran Li, Qiong Long, Hongmei Bai, Xu Yang, Zhaoling Ren et al. · 2021 · Nano Letters
100. Rapid and quantitative detection of SARS-CoV-2 IgG antibody in serum using optofluidic point-of-care testing fluorescence biosensor
     Dan Song, Jiayao Liu, Wenjuan Xu, Xiangzhi Han, Hongliang Wang, Yuan Cheng, Yuxin Zhuo, Feng Long · 2021 · Talanta